Ildong Holdings Co., Ltd. (000230.KS)
KRW 6600.0
(-5.44%)
KRW 6600.0
(-5.44%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -64.03 Billion KRW | 28.88% |
| 2022 | -116.29 Billion KRW | -49.4% |
| 2021 | -121.33 Billion KRW | -226.99% |
| 2020 | 16.48 Billion KRW | 117.67% |
| 2019 | -19.66 Billion KRW | 445.69% |
| 2018 | 2.27 Billion KRW | -41.59% |
| 2017 | 675.42 Million KRW | -52.35% |
| 2016 | 9.2 Billion KRW | -79.7% |
| 2015 | 13.34 Billion KRW | 41.99% |
| 2014 | 30.81 Billion KRW | -13.92% |
| 2013 | 36.24 Billion KRW | 10.26% |
| 2012 | 33.43 Billion KRW | -34.3% |
| 2011 | 48.6 Billion KRW | 5.14% |
| 2010 | 50.96 Billion KRW | -1.8% |
| 2009 | 50.28 Billion KRW | 68.33% |
| 2008 | 44.96 Billion KRW | -46.88% |
| 2007 | 56.14 Billion KRW | -6.06% |
| 2006 | 59.85 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 490 Million KRW | -95.87% |
| 2024 Q1 | 5.36 Billion KRW | 419.38% |
| 2024 Q3 | 105 Million KRW | -78.57% |
| 2023 Q3 | 48.09 Billion KRW | 393.68% |
| 2023 Q2 | -16.37 Billion KRW | -129.6% |
| 2023 Q1 | 55.33 Billion KRW | 409.08% |
| 2023 Q4 | 510.86 Million KRW | -98.94% |
| 2023 FY | - KRW | 28.88% |
| 2022 FY | - KRW | -49.4% |
| 2022 Q1 | -4.96 Billion KRW | 65.77% |
| 2022 Q2 | -19.57 Billion KRW | -294.45% |
| 2022 Q3 | -15.51 Billion KRW | 20.77% |
| 2022 Q4 | -17.9 Billion KRW | -15.43% |
| 2021 Q3 | -9.59 Billion KRW | -134.66% |
| 2021 Q4 | -14.49 Billion KRW | -51.17% |
| 2021 Q1 | -10.98 Billion KRW | -1639.64% |
| 2021 Q2 | -4.08 Billion KRW | 62.8% |
| 2021 FY | - KRW | -226.99% |
| 2020 Q4 | 713.58 Million KRW | -93.0% |
| 2020 FY | - KRW | 117.67% |
| 2020 Q1 | 5.78 Billion KRW | 118.34% |
| 2020 Q2 | 15.19 Billion KRW | 162.86% |
| 2020 Q3 | 10.19 Billion KRW | -32.95% |
| 2019 Q3 | -9.69 Billion KRW | -696.03% |
| 2019 FY | - KRW | 445.69% |
| 2019 Q2 | 1.62 Billion KRW | -76.2% |
| 2019 Q4 | -31.52 Billion KRW | -225.28% |
| 2019 Q1 | 6.83 Billion KRW | 523.24% |
| 2018 Q3 | 1.27 Billion KRW | 170.2% |
| 2018 Q1 | 684.77 Million KRW | -80.39% |
| 2018 FY | - KRW | -41.59% |
| 2018 Q4 | -1.61 Billion KRW | -226.52% |
| 2018 Q2 | 472.31 Million KRW | -31.03% |
| 2017 Q3 | -148.41 Million KRW | 79.29% |
| 2017 Q2 | -716.72 Million KRW | -217.81% |
| 2017 Q1 | 608.36 Million KRW | 149.07% |
| 2017 FY | - KRW | -52.35% |
| 2017 Q4 | 3.49 Billion KRW | 2452.81% |
| 2016 Q4 | -1.23 Billion KRW | 16.41% |
| 2016 FY | - KRW | -79.7% |
| 2016 Q3 | -1.48 Billion KRW | -250.63% |
| 2016 Q2 | 984.71 Million KRW | -89.58% |
| 2016 Q1 | 9.45 Billion KRW | 76.11% |
| 2015 FY | - KRW | 41.99% |
| 2015 Q1 | 13.02 Billion KRW | 39.11% |
| 2015 Q2 | 5.35 Billion KRW | -58.91% |
| 2015 Q3 | 6.6 Billion KRW | 23.5% |
| 2015 Q4 | 5.36 Billion KRW | -18.77% |
| 2014 Q4 | 9.36 Billion KRW | 10.92% |
| 2014 Q3 | 8.43 Billion KRW | 10.35% |
| 2014 Q2 | 7.64 Billion KRW | 10.43% |
| 2014 Q1 | 6.92 Billion KRW | -17.76% |
| 2014 FY | - KRW | -13.92% |
| 2013 FY | - KRW | 10.26% |
| 2013 Q4 | 8.42 Billion KRW | -39.34% |
| 2013 Q1 | 9.09 Billion KRW | -48.56% |
| 2013 Q3 | 13.88 Billion KRW | 123.58% |
| 2013 Q2 | 6.2 Billion KRW | -31.73% |
| 2012 FY | - KRW | -34.3% |
| 2012 Q4 | 17.67 Billion KRW | 228.24% |
| 2012 Q3 | 5.38 Billion KRW | -36.78% |
| 2012 Q2 | 8.52 Billion KRW | 138.9% |
| 2012 Q1 | 3.56 Billion KRW | 0.0% |
| 2011 FY | - KRW | 5.14% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q3 | 8.58 Billion KRW | -44.63% |
| 2011 Q1 | 16.42 Billion KRW | 0.0% |
| 2011 Q2 | 15.5 Billion KRW | -5.57% |
| 2010 Q1 | - KRW | -100.0% |
| 2010 FY | - KRW | -1.8% |
| 2010 Q3 | 14.91 Billion KRW | 18.93% |
| 2010 Q2 | 12.54 Billion KRW | 0.0% |
| 2009 FY | - KRW | 68.33% |
| 2009 Q2 | 9.56 Billion KRW | 0.0% |
| 2009 Q3 | 10.45 Billion KRW | 9.33% |
| 2009 Q4 | 16.22 Billion KRW | 55.16% |
| 2009 Q1 | - KRW | -100.0% |
| 2008 Q4 | 9.81 Billion KRW | -13.96% |
| 2008 Q2 | 7.72 Billion KRW | 0.0% |
| 2008 Q3 | 11.4 Billion KRW | 47.65% |
| 2008 Q1 | - KRW | -100.0% |
| 2008 FY | - KRW | -46.88% |
| 2007 Q3 | 12.42 Billion KRW | 31.63% |
| 2007 FY | - KRW | -6.06% |
| 2007 Q4 | 7.88 Billion KRW | -36.53% |
| 2007 Q2 | 9.43 Billion KRW | 0.0% |
| 2006 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 1418.065% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 145.299% |
| HANDOK Inc. | 35.06 Billion KRW | 282.612% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | -6077.657% |
| Yuhan Corporation | 127.43 Billion KRW | 150.251% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 270.667% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | -195.266% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 119.805% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | 1383.205% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 523.568% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | 1971.866% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | 1514.723% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | 280.452% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 1418.065% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | -246.669% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | 1076.909% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | -29.912% |
| JW Holdings Corporation | 187.88 Billion KRW | 134.083% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | -25.001% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 122.578% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 171.773% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | -72.758% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | 584.769% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | 641.4% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | 443.268% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 1418.065% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 216.486% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 138.83% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 171.773% |
| Yuhan Corporation | 127.43 Billion KRW | 150.251% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | 291.29% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | 937.091% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 183.133% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 171.773% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 274.797% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 190.472% |
| CKD Bio Corp. | -1.63 Billion KRW | -3827.524% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 228.605% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | 296.662% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 273.962% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | -72.758% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 202.813% |
| Boryung Corporation | 114.28 Billion KRW | 156.03% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | -109.485% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 523.568% |
| JW Lifescience Corporation | 50.82 Billion KRW | 225.983% |